De Mulder P H, Weissbach L, Jakse G, Osieka R, Blatter J
Department of Medical Oncology, University Hospital Nijmegen, The Netherlands.
Cancer Chemother Pharmacol. 1996;37(5):491-5. doi: 10.1007/s002800050417.
Gemcitabine is a fluorine-substituted cytarabine analog with broad experimental antitumor activity. It's activity was explored in chemotherapy-naive patients with advanced progressive renal-cell carcinoma. A total of 39 patients were included in the study, of whom 37 were fully evaluable. In five patients the primary tumor remained in situ. Gemcitabine at 800 mg/m2 was given as a weekly 30-min infusion for 3 consecutive weeks followed by 1 week of rest. One complete response and two partial responses were observed giving a response rate of 8.1% [95% confidence interval (CI), 2-22%]. The duration of the responses is currently 32, 15, and 19 months, respectively. The median survival for all patients was 12.3 months. Gemacitabine was generally well tolerated, with nausea and vomiting (20.5% grade III) and neutropenia (5.3% grade III) being the most significant side effects. Gemcitabine given at this dose level and on this schedule has only limited activity in advanced renal-cell carcinoma.
吉西他滨是一种氟代阿糖胞苷类似物，具有广泛的实验性抗肿瘤活性。在未经化疗的晚期进展性肾细胞癌患者中对其活性进行了研究。共有39例患者纳入该研究，其中37例可进行全面评估。5例患者的原发肿瘤仍处于原位。给予吉西他滨800mg/m²，每周输注30分钟，连续3周，随后休息1周。观察到1例完全缓解和2例部分缓解，缓解率为8.1%[95%置信区间(CI)，2-22%]。目前缓解持续时间分别为32、15和19个月。所有患者的中位生存期为12.3个月。吉西他滨总体耐受性良好，恶心和呕吐(20.5%为3级)以及中性粒细胞减少(5.3%为3级)是最显著的副作用。在此剂量水平和方案下给予吉西他滨在晚期肾细胞癌中仅具有有限的活性。
